Neuronetics (STIM) Registration Filing summary

Company overview and business model

• Operates as a global neuroscience company focused on mental health, offering in-office treatments using the NeuroStar Advanced Therapy System, a non-invasive TMS device FDA-cleared for major depressive disorder, OCD, and anxious depression in adults and adolescents.

• Acquired Greenbrook TMS Inc., expanding its network of treatment centers across the U.S. and broadening its service offerings to include SPRAVATO® for treatment-resistant depression.

• Claims the NeuroStar system is supported by the largest clinical data set among TMS competitors and emphasizes safety, efficacy, and reproducibility.

Financial performance and metrics

• As of June 30, 2025, 66,113,822 shares of common stock were outstanding; no preferred stock was outstanding.

• Net tangible book value as of March 31, 2025, was $0.03 per share; after the offering, it would increase to $0.62 per share, with immediate dilution of $2.80 per share to new investors at an assumed price of $3.42 per share.

• The company is classified as a "smaller reporting company" under SEC rules.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for working capital and general corporate purposes, with management retaining broad discretion over allocation.

• Pending use, proceeds may be invested in short-term, interest-bearing instruments or U.S. government obligations.